Intermittent Fasting in Metabolic Syndrome: Clinical Evidence, Molecular Mechanisms, and Future Perspectives

Clicks: 5
ID: 333409
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #42 of 42 articles by views in nutrition reviews

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract The objective for this narrative review was to synthesize and critically assess the clinical evidence, molecular mechanisms, and future directions of intermittent fasting (IF) for managing metabolic syndrome (MetS). Metabolic syndrome is a complex cardiometabolic disorder associated with abnormal dietary patterns, epigenetic regulation, and gene activity, and characterized by central adiposity, insulin resistance, hypertension, and dyslipidemia. Intermittent fasting regimens, including time-restricted eating, alternate-day fasting, and the 5:2 fasting regimen, are promising nutritional interventions. Nonetheless, large, randomized trials have reported mixed clinical outcomes, and critical uncertainties persist regarding clinical effectiveness, molecular mechanisms, and whether benefits arise from fasting timing or weight-loss-driven energy restriction. A comprehensive literature search was conducted in major databases through July 2026. Articles, including those reporting on randomized controlled trials, systematic reviews, meta-analyses, and relevant preclinical mechanistic investigations in MetS, were selected and their data synthesized. Findings show that certain IF regimens produce modest improvements in body weight, waist circumference, and selected cardiometabolic risk markers; however, effects on glycemic control, lipid profiles, and liver-related end points are heterogeneous across trials. Observed clinical responses vary by fasting protocol, participant phenotype, and adherence, and high-quality human mechanistic data remain limited. Mechanistic insights, largely derived from preclinical models, highlight circadian rhythm synchronization and nutrient-sensing network modulation as key biological pathways. Important unresolved controversies cover protocol optimization, long-term adherence, and inter-individual metabolic variability. Intermittent fasting may serve as a feasible nonpharmacological adjunct intervention for MetS and related conditions, yet existing evidence is inconsistent. Translation toward precision lifestyle medicine requires resolution of ongoing controversies, improved evaluation of evidence quality, development of personalized fasting protocols, and rigorous assessment of long-term safety and sustainability across diverse patient populations.
Reference Key
openalex_W7223206838 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lina PANG, Shufang Li, Xinyi Li, Xiang Mao, Meng Gong, Xiangyin Ye, Benhua Yu, ChunYan Gou
Journal nutrition reviews
Year 2026
DOI
10.1093/nutrit/nuag155
URL
https://doi.org/10.1093/nutrit/nuag155
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.